ziqih personal page - To The Moon

ziqih

No personal profile

6Follow

0Followers

0Topic

0Badge

2021-08-05

[What]

Sorry, the original content has been removed

2021-07-22

[What]

Biogen pushes back against critics of Alzheimer's drug as early sales hit $2 million

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585399425819484","uuid":"3585399425819484","gmtCreate":1622305401192,"gmtModify":1622305401192,"name":"ziqih","pinyin":"ziqih","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":899187040,"gmtCreate":1628169511280,"gmtModify":1703502456002,"author":{"id":"3585399425819484","authorId":"3585399425819484","name":"ziqih","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585399425819484","authorIdStr":"3585399425819484"},"themes":[],"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/899187040","repostId":"1129943184","repostType":4,"repost":{"id":"1129943184","pubTimestamp":1628168812,"share":"https://ttm.financial/m/news/1129943184?lang=&edition=fundamental","pubTime":"2021-08-05 21:06","market":"us","language":"en","title":"Roku Pays to Be a Player","url":"https://stock-news.laohu8.com/highlight/detail?id=1129943184","media":"The Wall Street Journal","summary":"Streaming star’s ad business delivers, but shortages remind why hardware still matters.\n\nInvestors g","content":"<blockquote>\n Streaming star’s ad business delivers, but shortages remind why hardware still matters.\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/0816e996a3dc8dabffbc82ab2a069899\" tg-width=\"882\" tg-height=\"512\" referrerpolicy=\"no-referrer\"><a href=\"https://laohu8.com/S/ISBC\">Investors</a> got a painful reminder Wednesday thatRokuROKU0.60%is still in the hardware business.</p>\n<p>It has been easy to forget. Roku may be best known to consumers for the TV sets and streaming boxes that bear its name, but advertising now makes up more than 80% of its total business. Advertising also is far more profitable, generating gross margins of 60% last year against 9% for the company’s hardware side.Roku’s business model has also made the company a Wall Street darling. The stock has surged 153% over the past 12 months and commands a multiple of more than 16 times forward sales—more than double that ofNetflix.</p>\n<p>But there is no room for error. Roku’s second-quarter results reported Wednesday afternoon were strong in many important respects. Platform revenue reflecting the company’s advertising business more than doubled year over year to $532 million—handily beating Wall Street’s projections. But player revenue fell short, rising only 1% year over year to about $113 million. Moreover, player gross margins went negative for only the second time in the company’s history. Roku said it had elected to insulate customers from the cost increases related to the component shortages and shipping constraints afflicting many other makers of electronics products.</p>\n<p>Roku’s share price slid more than 8% following the report. That dive might seem an overreaction, given the strength in the larger and more profitable ad side, but Roku’s hardware—which includes TV sets made by partners—serves as an important gateway to its platform. The company added 1.5 million active accounts during the quarter, the lowest growth in two years. Streaming hours over the Roku platform also slipped 5% from the first quarter—the first sequential decline for this metric on record.</p>\n<p>Roku still inhabits an enviable position in the streaming wars. The company powers about 38% of streaming devices and connected TVs in the U.S., according to Parks Associates, representing a leading market share over platforms backed by tech titansAmazon,Appleand Google. That share provides valuable advertising real estate to tech and media giants pushing their own streaming services as well as other advertisers cutting back on traditional TV spending. Roku said Wednesday that it earned double the dollar commitmentat this year’s Upfrontscompared with last year. The company just needs to get enough devices in front of the eyeballs that advertisers are paying to reach.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roku Pays to Be a Player</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoku Pays to Be a Player\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 21:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/roku-pays-to-be-a-player-11628157601?mod=markets_lead_pos11><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Streaming star’s ad business delivers, but shortages remind why hardware still matters.\n\nInvestors got a painful reminder Wednesday thatRokuROKU0.60%is still in the hardware business.\nIt has been easy...</p>\n\n<a href=\"https://www.wsj.com/articles/roku-pays-to-be-a-player-11628157601?mod=markets_lead_pos11\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROKU":"Roku Inc"},"source_url":"https://www.wsj.com/articles/roku-pays-to-be-a-player-11628157601?mod=markets_lead_pos11","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129943184","content_text":"Streaming star’s ad business delivers, but shortages remind why hardware still matters.\n\nInvestors got a painful reminder Wednesday thatRokuROKU0.60%is still in the hardware business.\nIt has been easy to forget. Roku may be best known to consumers for the TV sets and streaming boxes that bear its name, but advertising now makes up more than 80% of its total business. Advertising also is far more profitable, generating gross margins of 60% last year against 9% for the company’s hardware side.Roku’s business model has also made the company a Wall Street darling. The stock has surged 153% over the past 12 months and commands a multiple of more than 16 times forward sales—more than double that ofNetflix.\nBut there is no room for error. Roku’s second-quarter results reported Wednesday afternoon were strong in many important respects. Platform revenue reflecting the company’s advertising business more than doubled year over year to $532 million—handily beating Wall Street’s projections. But player revenue fell short, rising only 1% year over year to about $113 million. Moreover, player gross margins went negative for only the second time in the company’s history. Roku said it had elected to insulate customers from the cost increases related to the component shortages and shipping constraints afflicting many other makers of electronics products.\nRoku’s share price slid more than 8% following the report. That dive might seem an overreaction, given the strength in the larger and more profitable ad side, but Roku’s hardware—which includes TV sets made by partners—serves as an important gateway to its platform. The company added 1.5 million active accounts during the quarter, the lowest growth in two years. Streaming hours over the Roku platform also slipped 5% from the first quarter—the first sequential decline for this metric on record.\nRoku still inhabits an enviable position in the streaming wars. The company powers about 38% of streaming devices and connected TVs in the U.S., according to Parks Associates, representing a leading market share over platforms backed by tech titansAmazon,Appleand Google. That share provides valuable advertising real estate to tech and media giants pushing their own streaming services as well as other advertisers cutting back on traditional TV spending. Roku said Wednesday that it earned double the dollar commitmentat this year’s Upfrontscompared with last year. The company just needs to get enough devices in front of the eyeballs that advertisers are paying to reach.","news_type":1},"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172525179,"gmtCreate":1626967446891,"gmtModify":1703481641770,"author":{"id":"3585399425819484","authorId":"3585399425819484","name":"ziqih","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585399425819484","authorIdStr":"3585399425819484"},"themes":[],"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172525179","repostId":"1125518042","repostType":4,"repost":{"id":"1125518042","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626957784,"share":"https://ttm.financial/m/news/1125518042?lang=&edition=fundamental","pubTime":"2021-07-22 20:43","market":"us","language":"en","title":"Biogen pushes back against critics of Alzheimer's drug as early sales hit $2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1125518042","media":"Reuters","summary":"(Reuters) -Biogen Inc on Thursday mounted a defense of its interactions with U.S. regulators that le","content":"<p>(Reuters) -<a href=\"https://laohu8.com/S/BIIB\">Biogen</a> Inc on Thursday mounted a defense of its interactions with U.S. regulators that led to a controversial approval of its new Alzheimer’s treatment, as the company seeks to quell concerns about the drug’s effectiveness.</p>\n<p>The company recorded nearly $2 million in sales of the drug, which was approved on June 7, in the second quarter, while analysts on average had estimated $3.23 million, according to IBES data from Refinitiv.</p>\n<p>The decision by the U.S. Food and Drug Administration to approve Aduhelm despite its panel of outside experts recommending against it has drawn criticism, with the agency asking federal investigators to review the process.</p>\n<p>“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab. A better understanding of the facts is good for everyone involved,” Alfred Sandrock, head of research and development at Biogen, said in an open letter to the Alzheimer’s disease community.</p>\n<p>The company’s comments about the drug’s approval make it clear that there is “little chance of the controversy abating in the near term,” said Wedbush analyst Laura Chico.</p>\n<p>Aduhelm’s $56,000 per year price tag has also spurred lawmakers to launch a probe, with insurers waiting for clarity before starting coverage.</p>\n<p>The drugmaker expects modest revenue from Aduhelm this year and to ramp up thereafter, adding it was seeing “strong indications of very high initial patient interest as well as increased referrals.”</p>\n<p>Biogen now expects total sales of $10.65 billion to $10.85 billion this year, compared with its prior estimate of $10.45 billion to $10.75 billion.</p>\n<p>The company’s shares gained 1.1% to $326.50 in early trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen pushes back against critics of Alzheimer's drug as early sales hit $2 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen pushes back against critics of Alzheimer's drug as early sales hit $2 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-22 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -<a href=\"https://laohu8.com/S/BIIB\">Biogen</a> Inc on Thursday mounted a defense of its interactions with U.S. regulators that led to a controversial approval of its new Alzheimer’s treatment, as the company seeks to quell concerns about the drug’s effectiveness.</p>\n<p>The company recorded nearly $2 million in sales of the drug, which was approved on June 7, in the second quarter, while analysts on average had estimated $3.23 million, according to IBES data from Refinitiv.</p>\n<p>The decision by the U.S. Food and Drug Administration to approve Aduhelm despite its panel of outside experts recommending against it has drawn criticism, with the agency asking federal investigators to review the process.</p>\n<p>“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab. A better understanding of the facts is good for everyone involved,” Alfred Sandrock, head of research and development at Biogen, said in an open letter to the Alzheimer’s disease community.</p>\n<p>The company’s comments about the drug’s approval make it clear that there is “little chance of the controversy abating in the near term,” said Wedbush analyst Laura Chico.</p>\n<p>Aduhelm’s $56,000 per year price tag has also spurred lawmakers to launch a probe, with insurers waiting for clarity before starting coverage.</p>\n<p>The drugmaker expects modest revenue from Aduhelm this year and to ramp up thereafter, adding it was seeing “strong indications of very high initial patient interest as well as increased referrals.”</p>\n<p>Biogen now expects total sales of $10.65 billion to $10.85 billion this year, compared with its prior estimate of $10.45 billion to $10.75 billion.</p>\n<p>The company’s shares gained 1.1% to $326.50 in early trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125518042","content_text":"(Reuters) -Biogen Inc on Thursday mounted a defense of its interactions with U.S. regulators that led to a controversial approval of its new Alzheimer’s treatment, as the company seeks to quell concerns about the drug’s effectiveness.\nThe company recorded nearly $2 million in sales of the drug, which was approved on June 7, in the second quarter, while analysts on average had estimated $3.23 million, according to IBES data from Refinitiv.\nThe decision by the U.S. Food and Drug Administration to approve Aduhelm despite its panel of outside experts recommending against it has drawn criticism, with the agency asking federal investigators to review the process.\n“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab. A better understanding of the facts is good for everyone involved,” Alfred Sandrock, head of research and development at Biogen, said in an open letter to the Alzheimer’s disease community.\nThe company’s comments about the drug’s approval make it clear that there is “little chance of the controversy abating in the near term,” said Wedbush analyst Laura Chico.\nAduhelm’s $56,000 per year price tag has also spurred lawmakers to launch a probe, with insurers waiting for clarity before starting coverage.\nThe drugmaker expects modest revenue from Aduhelm this year and to ramp up thereafter, adding it was seeing “strong indications of very high initial patient interest as well as increased referrals.”\nBiogen now expects total sales of $10.65 billion to $10.85 billion this year, compared with its prior estimate of $10.45 billion to $10.75 billion.\nThe company’s shares gained 1.1% to $326.50 in early trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":899187040,"gmtCreate":1628169511280,"gmtModify":1703502456002,"author":{"id":"3585399425819484","authorId":"3585399425819484","name":"ziqih","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585399425819484","authorIdStr":"3585399425819484"},"themes":[],"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/899187040","repostId":"1129943184","repostType":4,"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172525179,"gmtCreate":1626967446891,"gmtModify":1703481641770,"author":{"id":"3585399425819484","authorId":"3585399425819484","name":"ziqih","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585399425819484","authorIdStr":"3585399425819484"},"themes":[],"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172525179","repostId":"1125518042","repostType":4,"repost":{"id":"1125518042","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626957784,"share":"https://ttm.financial/m/news/1125518042?lang=&edition=fundamental","pubTime":"2021-07-22 20:43","market":"us","language":"en","title":"Biogen pushes back against critics of Alzheimer's drug as early sales hit $2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1125518042","media":"Reuters","summary":"(Reuters) -Biogen Inc on Thursday mounted a defense of its interactions with U.S. regulators that le","content":"<p>(Reuters) -<a href=\"https://laohu8.com/S/BIIB\">Biogen</a> Inc on Thursday mounted a defense of its interactions with U.S. regulators that led to a controversial approval of its new Alzheimer’s treatment, as the company seeks to quell concerns about the drug’s effectiveness.</p>\n<p>The company recorded nearly $2 million in sales of the drug, which was approved on June 7, in the second quarter, while analysts on average had estimated $3.23 million, according to IBES data from Refinitiv.</p>\n<p>The decision by the U.S. Food and Drug Administration to approve Aduhelm despite its panel of outside experts recommending against it has drawn criticism, with the agency asking federal investigators to review the process.</p>\n<p>“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab. A better understanding of the facts is good for everyone involved,” Alfred Sandrock, head of research and development at Biogen, said in an open letter to the Alzheimer’s disease community.</p>\n<p>The company’s comments about the drug’s approval make it clear that there is “little chance of the controversy abating in the near term,” said Wedbush analyst Laura Chico.</p>\n<p>Aduhelm’s $56,000 per year price tag has also spurred lawmakers to launch a probe, with insurers waiting for clarity before starting coverage.</p>\n<p>The drugmaker expects modest revenue from Aduhelm this year and to ramp up thereafter, adding it was seeing “strong indications of very high initial patient interest as well as increased referrals.”</p>\n<p>Biogen now expects total sales of $10.65 billion to $10.85 billion this year, compared with its prior estimate of $10.45 billion to $10.75 billion.</p>\n<p>The company’s shares gained 1.1% to $326.50 in early trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen pushes back against critics of Alzheimer's drug as early sales hit $2 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen pushes back against critics of Alzheimer's drug as early sales hit $2 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-22 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -<a href=\"https://laohu8.com/S/BIIB\">Biogen</a> Inc on Thursday mounted a defense of its interactions with U.S. regulators that led to a controversial approval of its new Alzheimer’s treatment, as the company seeks to quell concerns about the drug’s effectiveness.</p>\n<p>The company recorded nearly $2 million in sales of the drug, which was approved on June 7, in the second quarter, while analysts on average had estimated $3.23 million, according to IBES data from Refinitiv.</p>\n<p>The decision by the U.S. Food and Drug Administration to approve Aduhelm despite its panel of outside experts recommending against it has drawn criticism, with the agency asking federal investigators to review the process.</p>\n<p>“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab. A better understanding of the facts is good for everyone involved,” Alfred Sandrock, head of research and development at Biogen, said in an open letter to the Alzheimer’s disease community.</p>\n<p>The company’s comments about the drug’s approval make it clear that there is “little chance of the controversy abating in the near term,” said Wedbush analyst Laura Chico.</p>\n<p>Aduhelm’s $56,000 per year price tag has also spurred lawmakers to launch a probe, with insurers waiting for clarity before starting coverage.</p>\n<p>The drugmaker expects modest revenue from Aduhelm this year and to ramp up thereafter, adding it was seeing “strong indications of very high initial patient interest as well as increased referrals.”</p>\n<p>Biogen now expects total sales of $10.65 billion to $10.85 billion this year, compared with its prior estimate of $10.45 billion to $10.75 billion.</p>\n<p>The company’s shares gained 1.1% to $326.50 in early trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125518042","content_text":"(Reuters) -Biogen Inc on Thursday mounted a defense of its interactions with U.S. regulators that led to a controversial approval of its new Alzheimer’s treatment, as the company seeks to quell concerns about the drug’s effectiveness.\nThe company recorded nearly $2 million in sales of the drug, which was approved on June 7, in the second quarter, while analysts on average had estimated $3.23 million, according to IBES data from Refinitiv.\nThe decision by the U.S. Food and Drug Administration to approve Aduhelm despite its panel of outside experts recommending against it has drawn criticism, with the agency asking federal investigators to review the process.\n“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab. A better understanding of the facts is good for everyone involved,” Alfred Sandrock, head of research and development at Biogen, said in an open letter to the Alzheimer’s disease community.\nThe company’s comments about the drug’s approval make it clear that there is “little chance of the controversy abating in the near term,” said Wedbush analyst Laura Chico.\nAduhelm’s $56,000 per year price tag has also spurred lawmakers to launch a probe, with insurers waiting for clarity before starting coverage.\nThe drugmaker expects modest revenue from Aduhelm this year and to ramp up thereafter, adding it was seeing “strong indications of very high initial patient interest as well as increased referrals.”\nBiogen now expects total sales of $10.65 billion to $10.85 billion this year, compared with its prior estimate of $10.45 billion to $10.75 billion.\nThe company’s shares gained 1.1% to $326.50 in early trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}